Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2014

Open Access 01-12-2014 | Case report

Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report

Authors: Sung UK Baek, Soon IL Kwon

Published in: Journal of Medical Case Reports | Issue 1/2014

Login to get access

Abstract

Introduction

We describe the case of a man who died of an abdominal aortic aneurysm rupture after an intravitreal injection of bevacizumab for neovascular age-related macular degeneration.

Case presentation

A 74-year-old Korean man presented with visual disturbance in his right eye. He had previously been diagnosed with diabetes and hypertension, which were controlled with oral medications. We diagnosed him with neovascular age-related macular degeneration and he was treated by monthly intravitreal injection of bevacizumab for three months. Four days after his third intravitreal bevacizumab injection, he died of an abdominal aortic aneurysm rupture and uncontrolled bleeding.

Conclusion

Abdominal aortic aneurysm rupture is highly lethal and there is a possible correlation with intravitreal injection of bevacizumab. Thus, we need to consider the risks of intravitreal bevacizumab injections for patients with abdominal aortic aneurysms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Carneiro AM, Barthelmes D, Falcão MS, Mendonça LS, Fonseca SL, Gonçalves RM, Faria-Correia F, Falcão-Reis FM: Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011, 225: 211-221. 10.1159/000323943.CrossRefPubMed Carneiro AM, Barthelmes D, Falcão MS, Mendonça LS, Fonseca SL, Gonçalves RM, Faria-Correia F, Falcão-Reis FM: Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011, 225: 211-221. 10.1159/000323943.CrossRefPubMed
2.
go back to reference Wu L, Martinez-Castellanos MA, Quiroz-Mercado H: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe’s Arch Clin Exp Ophthalmol. 2008, 246: 81-87.CrossRef Wu L, Martinez-Castellanos MA, Quiroz-Mercado H: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe’s Arch Clin Exp Ophthalmol. 2008, 246: 81-87.CrossRef
3.
go back to reference Curtis LH, Hammill BG, Schulman KA: Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010, 128: 1273-1279. 10.1001/archophthalmol.2010.223.CrossRefPubMed Curtis LH, Hammill BG, Schulman KA: Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010, 128: 1273-1279. 10.1001/archophthalmol.2010.223.CrossRefPubMed
4.
go back to reference Bressler NM: Age-related macular degeneration is the leading cause of blindness. JAMA. 2004, 291: 1900-1901. 10.1001/jama.291.15.1900.CrossRefPubMed Bressler NM: Age-related macular degeneration is the leading cause of blindness. JAMA. 2004, 291: 1900-1901. 10.1001/jama.291.15.1900.CrossRefPubMed
5.
go back to reference Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004, 25: 581-611. 10.1210/er.2003-0027.CrossRefPubMed Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004, 25: 581-611. 10.1210/er.2003-0027.CrossRefPubMed
6.
go back to reference Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005, 25: 111-118. 10.1097/00006982-200502000-00001.CrossRefPubMed Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005, 25: 111-118. 10.1097/00006982-200502000-00001.CrossRefPubMed
7.
go back to reference Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005, 36: 331-335.PubMed Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005, 36: 331-335.PubMed
8.
go back to reference Avery RL, Pieramici DJ, Rabena MD: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006, 113: 363-372. 10.1016/j.ophtha.2005.11.019.CrossRefPubMed Avery RL, Pieramici DJ, Rabena MD: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006, 113: 363-372. 10.1016/j.ophtha.2005.11.019.CrossRefPubMed
9.
go back to reference Rosenfeld PJ, Brown DM, Heier JS: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355: 1419-1431. 10.1056/NEJMoa054481.CrossRefPubMed Rosenfeld PJ, Brown DM, Heier JS: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355: 1419-1431. 10.1056/NEJMoa054481.CrossRefPubMed
10.
go back to reference Brown DM, Kaiser PK, Michels M: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355: 1432-1444. 10.1056/NEJMoa062655.CrossRefPubMed Brown DM, Kaiser PK, Michels M: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355: 1432-1444. 10.1056/NEJMoa062655.CrossRefPubMed
11.
go back to reference Bakri SJ, Snyder MR, Reid JM: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007, 114: 855-859. 10.1016/j.ophtha.2007.01.017.CrossRefPubMed Bakri SJ, Snyder MR, Reid JM: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007, 114: 855-859. 10.1016/j.ophtha.2007.01.017.CrossRefPubMed
12.
go back to reference Stewart MW: Predicted biologic activity of intravitreal bevacizumab. Retina. 2007, 27: 1196-1200. 10.1097/IAE.0b013e318158ea28.CrossRefPubMed Stewart MW: Predicted biologic activity of intravitreal bevacizumab. Retina. 2007, 27: 1196-1200. 10.1097/IAE.0b013e318158ea28.CrossRefPubMed
13.
go back to reference Lindholt JS, Heickendorff L, Antonsen S, Fasting H, Henneberg EW: Natural history of abdominal aortic aneurysm with and without coexisting chronic obstructive pulmonary disease. J Vasc Surg. 1998, 28: 226-233. 10.1016/S0741-5214(98)70158-2.CrossRefPubMed Lindholt JS, Heickendorff L, Antonsen S, Fasting H, Henneberg EW: Natural history of abdominal aortic aneurysm with and without coexisting chronic obstructive pulmonary disease. J Vasc Surg. 1998, 28: 226-233. 10.1016/S0741-5214(98)70158-2.CrossRefPubMed
14.
go back to reference Palm SJ, Russwurm GP, Chang D, Rozenblit AM, Ohki T, Veith FJ: Acute enlargement and subsequent rupture of an abdominal aortic aneurysm in a patient receiving chemotherapy for pancreatic carcinoma. J Vasc Surg. 2000, 32: 197-200. 10.1067/mva.2000.105665.CrossRefPubMed Palm SJ, Russwurm GP, Chang D, Rozenblit AM, Ohki T, Veith FJ: Acute enlargement and subsequent rupture of an abdominal aortic aneurysm in a patient receiving chemotherapy for pancreatic carcinoma. J Vasc Surg. 2000, 32: 197-200. 10.1067/mva.2000.105665.CrossRefPubMed
15.
go back to reference Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT: Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004, 110: 16-21. 10.1161/01.CIR.0000133279.07468.9F.CrossRefPubMed Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT: Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004, 110: 16-21. 10.1161/01.CIR.0000133279.07468.9F.CrossRefPubMed
16.
go back to reference Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor/vascular permeability via nitric oxide and prostacyclin. Circulation. 1998, 97: 99-107. 10.1161/01.CIR.97.1.99.CrossRefPubMed Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor/vascular permeability via nitric oxide and prostacyclin. Circulation. 1998, 97: 99-107. 10.1161/01.CIR.97.1.99.CrossRefPubMed
17.
go back to reference Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vas Biol. 2002, 22: 1500-1505. 10.1161/01.ATV.0000030186.66672.36.CrossRef Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vas Biol. 2002, 22: 1500-1505. 10.1161/01.ATV.0000030186.66672.36.CrossRef
Metadata
Title
Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report
Authors
Sung UK Baek
Soon IL Kwon
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-8-48

Other articles of this Issue 1/2014

Journal of Medical Case Reports 1/2014 Go to the issue